Somatotropin Deficiency Pipeline Insight

DelveInsight’s, “Somatotropin Deficiency – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Somatotropin Deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Somatotropin Deficiency Understanding

Somatotropin Deficiency: Overview

Somatotropin also known as growth hormone is about 190 amino acid long and is synthesized and secreted by somatotroph cells present in anterior pituitary. Somatotropin plays a major role in certain complex physiological processes such as growth and metabolism. Inadequate secretion of somatotropin hormone can lead to growth hormone deficiency or Somatotropin Deficiency in humans. The disease can either be present from birth (congenital) due to genetic mutations or from structural defects in brain or else can be acquired in later stage of life owing to tumors in pituitary, radiations, central nervous system infections, or severe head injuries. Somatotropin Deficiency affects male and female population equally except for GHD III which only affects male population.


Symptoms can include slow growth or absent of growth, delay in development of facial bones, delayed lengthening of long bones, slow teeth eruption, decreased energy levels, increase in abdominal and visceral fat mass, and anxiety.


Diagnosing Somatotropin Deficiency can be done by evaluating the growth hormone level through blood test. However, lower than normal level is not enough evidence for diagnosis as growth hormone level widely fluctuate during day and night. Therefore, diagnosing Somatotropin Deficiency also requires assessments of growth plate development via X-rays, MRI scans to check for tumors in pituitary, any head injury, and genetic testing for determining genetic mutations.


Treatments for Somatotropin Deficiency currently include dosage of recombinant human growth hormone to optimize the growth potential. Initially, the dosage is gradually increased to its highest dose during puberty and is discontinued at completion of skeletal maturation. Later the patient may require retesting for further recombinant therapy. Some of the FDA approved drugs for the treatment of Somatotropin Deficiency includes Nutropin, Norditropin, Genotropin, and others..

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Somatotropin Deficiency R&D. The therapies under development are focused on novel approaches to treat/improve Somatotropin Deficiency.

Somatotropin Deficiency Emerging Drugs Chapters

This segment of the Somatotropin Deficiency report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Somatotropin Deficiency Emerging Drugs

Ethansomatropin (GX-H9): Genexine

Genexine’s drug candidate, Ethansomatropin (GX-H9), is a class of recombinant somatropin fusion protein molecule in phase III for the treatment of Somatotropin Deficiency. The drug stimulates the production of insulin-like growth factor-1 in the liver, which has growth-stimulating effects on various tissues and increases the activities of osteoclast, and chondrocytes tissues thus stimulating bone growth.

Ibutamoren (LUM-201): Lumos Pharma

Lumos Pharma’s “breakthrough” drug Ibutamoren (LUM-201) is currently being evaluated for the treatment of Somatotropin Deficiency and has demonstrated good safety and efficacy profile in phase II trials. Ibutamoren is an orphan drug and is a growth hormone releasing factor agonists.

Further product details are provided in the report……..

Somatotropin Deficiency: Therapeutic Assessment

This segment of the report provides insights about the different Somatotropin Deficiency drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Somatotropin Deficiency

There are approx. 10+ key companies which are developing the therapies for Somatotropin Deficiency. The companies which have their Somatotropin Deficiency drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Genexine and others.


DelveInsight’s report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Somatotropin Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Somatotropin Deficiency: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Somatotropin Deficiency therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Somatotropin Deficiency drugs.

Somatotropin Deficiency Report Insights

  • Somatotropin Deficiency Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Somatotropin Deficiency Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Somatotropin Deficiency drugs?
  • How many Somatotropin Deficiency drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Somatotropin Deficiency?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Somatotropin Deficiency therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Somatotropin Deficiency and their status?
  • What are the key designations that have been granted to the emerging drugs?


Executive Summary

Somatotropin Deficiency: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Somatotropin Deficiency – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Somatotropin Deficiency companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Somatotropin Deficiency Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Eftansomatropin (GX-H9): Genexine

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Ibutamoren (LUM-201):

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Somatotropin Deficiency Key Companies

Somatotropin Deficiency Key Products

Somatotropin Deficiency- Unmet Needs

Somatotropin Deficiency- Market Drivers and Barriers

Somatotropin Deficiency- Future Perspectives and Conclusion

Somatotropin Deficiency Analyst Views

Somatotropin Deficiency Key Companies


List of Table

Table 1: Total Products for Somatotropin Deficiency

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Somatotropin Deficiency

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Lumos Pharma

• Genexine

• Novo Nordisk

• OPKO health

• Aravive

  • Tags:
  • Somatotropin Deficiency Pipeline
  • Somatotropin Deficiency clinical t...
  • Somatotropin Deficiency companies
  • Somatotropin Deficiency drugs
  • Somatotropin Deficiency therapies
  • Somatotropin Deficiency treatment...
  • Somatotropin Deficiency pipeline d...
  • Somatotropin Deficiency pipeline c...

Forward to Friend

Need A Quote